Previous 10 | Next 10 |
ATLANTA, June 03, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, Alimera’s President and C...
Start Time: 09:00 End Time: 09:40 Alimera Sciences, Inc. (ALIM) Q1 2020 Earnings Conference Call April 30, 2020, 09:00 AM ET Company Participants Rick Eiswirth - President and CEO Phil Jones - CFO Jules Abraham - CORE IR Conference Call Participants Andrew D’Silv...
Image source: The Motley Fool. Alimera Sciences Inc (NASDAQ: ALIM) Q1 2020 Earnings Call Apr 30, 2020 , 9:00 a.m. ET Operator Continue reading
Alimera Sciences (NASDAQ: ALIM ): Q1 GAAP EPS of -$0.24 beats by $0.32 . More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
First Quarter and Recent Company Highlights: Consolidated Net Revenue Up 12% Compared to First Quarter 2019 International Net Revenue Up 23% Compared to First Quarter 2019 Net Loss of $1.2 Million vs. Net Loss of $2.8 million in First Quarter 2019 $1.3 Million Positi...
ATLANTA, April 24, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report first quarter 2020 financial results ...
ATLANTA, April 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces it receive...
Thinly traded nano cap Alimera Sciences ( ALIM +19.2% ) is up in early trade, albeit on below-average volume, in reaction to preliminary Q1 revenue of more than $14M, up almost 9% from a year ago and above consensus of $12.9M. More news on: Alimera Sciences, Inc., Healthcare stocks new...
Alimera Sciences (NASDAQ: ALIM ) +2.2% pre-market, expects Q1 revenue to exceed $14M, compared to $12.9 last year quarter More news on: Alimera Sciences, Inc., Healthcare stocks news, Read more ...
ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line r...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...